The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma

Advances in Anatomic Pathology

Volumn 3, Issue 5, 1996, Pages 273-293

  Ordóñez, Nelson G ^a   Mackay, Bruce ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adenocarcinoma; Diagnosis; Electron microscopy; Immunohistochemistry; Mesothelioma

Indexed keywords

EID: 84890921445     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-199609000-00001     Document Type: Review

References (130)

1. Ruffie PA. Pleural mesothelioma. Curr Opin Oncol 1991;3:328-34.
2. Torikata C, Kawai T, Nakayama M. Confronting cisternae and ciliated cells in malignant pleural mesothelioma: an ultrastructural study. Ultrastruct Pathol 1991;15:249-56.
3. Walz R, Koch HK. Malignant pleural mesothelioma: Some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985. Pathol Res Pract 1990;186:124-34.
4. Musk AW, Dolin PJ, Armstrong BK, Ford JM, de Klerk NH, Hobbs MS. The incidence of malignant mesothelioma in Australia, 1947-1980. Med J Aust 1989;150:242-3, 246.
5. Rusch VW. Clinical features and current treatment of diffuse malignant pleural mesothelioma. Lung Cancer 1995;12(Suppl 2):S127-46.
6. Kwee WS, Veldhuizen RW, Golding RP. et al. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining. Virchows Arch [A] 1982;397:287-99.
7. Ehya H. The cytologic diagnosis of mesothelioma. Semin Diagn Pathol 1986;3:196-203.
8. Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988;138:184-234.
9. Hammar SP. Pleural diseases. In: Dail DH, Hammar SP (eds.). Pulmonary pathology, 2nd ed. New York: Springer-Verlag, 1994, pp 1463-579.
10. Dewar A, Valente M, Ring NP, Corrin B. Pleural mesothelioma of epithelial type and pulmonary adenocarcinoma: an ultrastructural and cytochemical comparison. J Pathol 1987;152:309-16.
11. Azumi N, Underhill CB, Kagan E, Sheibani K. A novel biotinylated probe specific for hyaluronate. Its diagnostic value in diffuse malignant mesothelioma. Am J Surg Pathol 1992;16:116-21.
12. Sandberg AA, Bridge JA. Mesothelioma. In: The cytogenetics of bone and soft tissue tumors. Austin, TX: R. G. Landes, 1994, pp 371-400.
13. Marchevsky AM. Gil J, Caccamo D. Computerized interactive morphometry. A study of malignant mesothelioma and mesothelial hyperplasia in pleural biopsy specimens. Arch Pathol Lab Med 1985;109:1102-5.
14. Burmer GC, Rabinovitch PS, Kulander BG, et al. Flow cytometric analysis of malignant pleural mesotheliomas. Hum Pathol 1989;20:777-83.
15. Tammilehto L. Malignant mesothelioma: prognostic factors in a prospective study of 98 patients. Lung Cancer 1992;8:175-84.
16. el-Naggar AK, Ordóñez NG, Garnsey L, Batsakis JG. Epithelioid pleural mesotheliomas and pulmonary adenocarcinomas: a comparative DNA flow cytometric study. Hum Pathol 1991;22:972-8.
17. Pyrhönen S, Laasonen A, Tammilehto L, et al. Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma. Eur J Cancer 1991;27:197-200.
18. Whitaker D, Manning LS, Robinson BWS, Shilkin KB. The pathobiology of the mesothelium. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D (eds.). Malignant Mesothelioma. New York: Hemisphere, 1992, pp 25-68.
19. Bolen JW, Hammar SP, McNutt MA. Reactive and neoplastic serosal tissue. A light-microscopic, ultrastructural, and immunocytochemical study. Am J Surg Pathol 1986;10:34-47.
20. Bolen JW, Hammar SP, McNutt MA. Serosal tissue: reactive tissue as a model for understanding mesotheliomas. Ultrastruct Pathol 1987;11:251-62.
21. Leong AS-Y, Vernon-Roberts E. The immunohistochemistry of malignant mesothelioma. Pathol Annu 1994:29 (part 2):157-79.
22. Blobel GA. Moll R, Franke WW, Kayser KW, Gould VE. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 1985;121:235-47.
23. Moll R, Dhouailly D, Sun TT. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody AE14. Virchows Arch 1989;58:129-45.
24. Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am J Surg Pathol 1985;9:360-5.
25. Mullink H, Henzen-Logmans SC, Alons-van Kordelaar JJM, Tadema TM, Meijer CJLM. Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma. Virchows Arch [B] 1986;52:55-65.
26. Jasani B, Edwards RE, Thomas ND, Gibbs AR. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Virchows Arch [A] 1985;406:441-8.
27. Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis. APMIS 1994;102:255-64.
28. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma. Am J Surg Pathol 1989;13:276-91.
29. Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol 1994;25:753-7.
30. Sloane JP, Ormerod MG. Distribution of epithelial membrane antigen in normal and neoplastic tissue and its value in diagnostic tumor pathology. Cancer 1981;47:1786-95.
31. Russo J, Russo IH. Immunocytochemical markers in breast cancer. In: DeLellis RA (ed.). Advances in immunohistochemistry. New York: Raven Press, 1988, pp 431-75.
32. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. Highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988;263:12820-3.
33. Taylor-Papadimitriou J, Gendler SJ. Molecular aspects of mucins. Cancer Rev 1988;11/12:11-24.
34. Battifora H, Kopinski MI. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach. Cancer 1985;55:1679-85.
35. Marshall RJ, Herbert A, Braye SG. Jones DB. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium. J Clin Pathol 1984;37:1215-21.
36. Weiss LM, Battifora H. The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma. Hum Pathol 1993;24:345-6 (letter).
37. Tron V, Wright JL. CEA and HMFG protein staining of malignant mesothelioma and adenocarcinoma of the lung. Arch Pathol Lab Med 1987;111:291-3.
38. Wirth PR, Legier J, Wright GL. Immunohistochemical evaluation of seven antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 1991;67:655-62.
39. Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol 1987;18:67-74.
40. Otis CN, Carter D, Cole S, Battifora H. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. Am J Surg Pathol 1987;11:445-56.
41. Gaffey MJ, Mills SE, Swanson PE, Zarbo RJ, Shah AR, Wick MR. Immunoreactivity for Ber-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol 1992;16:593-9.
42. Loosli H, Hurlimann J. Immunohistological study of malignant diffuse mesotheliomas of the pleura. Histopathology 1984;8:793-803.
43. Ghosh AK, Gatter KC, Dunnill MS, Mason DY. Immunohistologic staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies. J Clin Pathol 1987;40:19-25.
44. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987;47:5476-82.
45. SooHoo WEJ, Ordóñez NG. Expression of the core protein of polymorphic epithelial mucin as detected by SM-3 antibody in pulmonary adenocarcinoma and pleural malignant mesothelioma. (Abstr) Lab Invest 1992;66:116A.
46. Wick MR, Loy T, Mills SE, Legier JF. Manifel JC. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 1990;21:759-66.
47. Chenard-Neu MP, Bellocq JP, Maier A, Batzenschlager A. Mésothéliomes malins de la plévre. Analyse de leurs aspects immunohistochemiques. Ann Pathol 1990;10:20-7.
48. Colcher D, Hand PH, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with mammary tumor cells. Proc Natl Acad Sci USA 1981;78:3199-203.
49. Johnson VG, Schlom J. Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986;46:850-7.
50. Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW. Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986;76:995-1006.
51. Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J. Use of monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. Cancer Res 1985;45:1894-900.
52. Nuti M, Teramoto YA, Mariani-Costantini R, Hand PH, Colcher D, Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 1982;29:539-45.
53. Latza U, Niedobitek G, Schwarting R, Nekarda R, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 1990;43:213-9.
54. r 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883-91.
55. r 34,000 is a widely distributed human carcinoma marker. Br J Cancer 1987;56:714-21.
56. Sheibani K, Shin SS, Kezirian J, Weiss LM. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 1991;15:779-84.
57. Vortmeyer AO, Preuss J. Padberg B-C, Kastendieck H, Schröder S. Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas - a clinicomorphological study of 158 cases. Anticancer Res 1991;11:889-94.
58. Moch H, Oberholzer H, Dalquen N, Wegmann W. Gudat F. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. I. Immunohistochemical findings. Virchows Arch [A] 1993;423:19-27.
59. Radosevich JA, Ma Y. Lee I, Salwen H, Gould VE, Rosen ST. Monoclonal antibody 44-3A6 as a probe for a novel antigen found in human lung carcinomas with glandular differentiation. Cancer Res 1985;45:5808-12.
60. Lee I, Radosevich JA, Chejfec G, et al. Malignant mesotheliomas: improved differential diagnosis from lung adenocarcinomas using monoclonal antibody 44-3A6 and 624A12. Am J Pathol 1986;123:497-507.
61. Spagnolo DV, Whitaker D, Carrello S, Radosevich JA, Rosen ST, Gould VE. The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma. Am J Clin Pathol 1991;95:322-9.
62. Kawai T, Suzuki M, Torikata C, Suzuki Y. Expression of blood group-related antigens and heliz pomatia agglutinin in malignant, pleural mesothelioma and pulmonary adenocarcinomas. Hum Pathol 1991;22:118-24.
63. Noguchi M, Nakajima T, Hirohashi S, Akiba T, Shimosato Y. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewis", and anti-Tn antibodies. Hum Pathol 1989;20:53-7.
64. y, in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989;135:931-7.
65. Wang N, Huang S, Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma. An immunohistochemical differentiation from other lung cancers. Cancer 1979;44:937-43.
66. Whitaker D. Sterrett GF. Shilkin KB. Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma. Pathology 1982;14:255-8.
67. Gibbs AR, Harach R, Wagner JC, Jasani B. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma. Thorax 1985;40:91-5.
68. Friemann J, Otto H, Müller KM. Immunhistochemische Befunde zur Differentialdiagnose primärer und sekundärer Pleuratumoren. Verh Dtsch Ges Pathol 1986;70:311-6.
69. Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol 1986;123:212-4.
70. Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993;24:347-54.
71. Corson JM, Pinkus GS. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen. An immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am J Pathol 1982;108:80-7.
72. Said JW, Nash G, Tepper G, Banks-Schlegel S. Keratin proteins and carcinoembryonic antigen in lung carcinoma: an immunoperoxidase study of 54 cases, with ultrastructural correlations. Hum Pathol 1983;14:70-6.
73. Holden J, Churg A. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am J Surg Pathol 1984;8:277-4.
74. Wittekind C. Carcinoembryonic antigen family members as diagnostic tools in immunohistopathology. Tumor Biol 1995;16:42-7.
75. Thompson JA, Grunert F, Zimmerman W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344-66.
76. Nagel G, Grunert F. From genes to proteins: the nonspecific cross-reacting antigens. Tumor Biol 1995;16:17-22.
77. Dejmek A, Hjerpe A. Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies. Cancer 1994;73:464-9.
78. Ascoli V, Scalzo CC, Facciolo F, Nardi F. Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions. Acta Cytol 1995;39:613-22.
79. Pfaltz M, Odermatt B, Christen B, Ruttner JR. Immunohistochemistry in the diagnosis of malignant mesothelioma. Virchows Arch [A] 1987;411:387-93.
80. Hsu SM, Huang LC, Hsu PL, et al. Biochemical and ultrastructural study of Leu-M1 antigen in Reed-Sternberg cells: comparison with granulocytes and interdigitating reticulum cells. J Natl Cancer Inst 1986;77:363-70.
81. Pinkus GS, Said JW. Leu-M1 immunoreactivity in nonhematopoietic neoplasms and myeloproliferative disorders: an immunoperoxidase study of paraffin sections. Am J Clin Pathol 1986;85:278-82.
82. Sheibani K, Battifora H, Burke JS, Rappaport H. Leu-M1 antigen in human neoplasms: an immunohistologic study of 400 cases. Am J Surg Pathol 1986;10:227-36.
83. Wick MR, Mills SE, Swanson PE. Expression of "myelomonocytic" antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces. Am J Clin Pathol 1990;94:18-26.
84. Warnock ML, Stoloff A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. Am J Pathol 1988;133:30-8.
85. Stahel RA, O'Hara CJ, Waibel R, Martin A. Monoclonal antibodies against mesothelial membrane antigen discriminate between mesothelioma and lung adenocarcinoma. Int J Cancer 1988;41:218-23.
86. O'Hara CJ, Corson JM, Pinkus GS, Stahel RA. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am J Pathol 1990;136:421-8.
87. Miettinen M, Kovatich AJ. HBME-1 - a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft tissue and bone tumors. Appl Immunohistochem 1995;3:115-22.
88. Savera AT, Raju U, Linden MD. Mesothelioma vs. adenocarcinoma: diagnostic utility of HBME-1. Lab Invest 1996;74:162A (abstract).
89. King RJ. Composition and metabolism of the apolipoproteins of pulmonary surfactant. Annu Rev Physiol 1985;47:775-88.
90. Hawgood S, Clements JA. Pulmonary surfactant and its apoproteins. J Clin Invest 1990;86:1-6.
91. Kuan SF, Rust K, Crouch E. Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D in an Escherichia coli-binding protein in bronchoalveolar lavage. J Clin Invest 1992;90:97-106.
92. Walker SR, Williams MC, Benson B. Immunocytochemical localization of the major surfactant apoprotein in type II cells, Clara cells and alveolar macrophages of rat lung. J Histochem Cytochem 1986;34:1137-48.
93. Weaver TE, Whitsett JA. Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem J 1991;273:249-64.
94. Williams MC, Dobbs LG. Expression of cell-specific markers for alveolar epithelium in fetal rat lung. Am J Respir Cell Mol Biol 1990;2:533-42.
95. Singh G, Singh J, Ordóñez NG, et al. Expression of a 130-kDa mesothelial and ciliated cell Ag (MCp130) in normal and developing human and rat lung and its role as a diagnostic marker for mesotheliomas and tumors of the female reproductive system. Lab Invest 1995;73:48-58.
96. Maruyama I, Bell C, Majerus P. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncitiotrophoblasts of human placenta. J Cell Biol 1985;101:363-71.
97. Collins CL, Ordóñez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992;141:827-33.
98. Harris JP, South MA. Secretory component: a glandular epithelial cell marker. Am J Pathol 1981;105:47-53.
99. Poger ME, Hirsch BR, Lamm ME. Synthesis of secretory component by colonic neoplasms. Am J Pathol 1976;82:327-38.
100. Ernst CS, Brooks JJ. Immunoperoxidase localization of secretory component in reactive mesothelium and mesotheliomas. J Histochem Cytochem 1981;29:1102-4.
101. Kondi-Paphitis A, Addis BJ. Secretory component in pulmonary adenocarcinoma and mesothelioma. Histopathology 1986;10:1279-87.
102. Ohshio G, Yamaki K, Imamura T, et al. Distribution of the carbohydrate antigens, DU-PAN-2 and CA19-9, in tumors of the lung. Tumori 1995;81:67-73.
103. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259-68.
104. Chang K, Pai LH, Batra JK. Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992;52:181-6.
105. Souhami RL, Beverley PCL, Bobrow LG, Ledermann JA. Antigens of lung cancer: results of the Second International Workshop on Lung Cancer Antigens. J Natl Cancer Inst 1991;83:609-12.
106. Delahaye M, Hoogsteden HC, van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol 1991;165:137-43.
107. Ruitenbeek T, Gouw ASH, Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 1994;118:265-9.
108. Fleuren GJ, Coerkamp EG, Nap M, van der Broek UCM, Warnaar SO. Immunohistological characterization of a monoclonal antibody (OV632) against epithelial ovarian carcinomas. Virchows Arch [A] 1987;410:481-6.
109. Koelma IA, Nap M, van Steenis GJ, Fleuren GJ. Tumor markers for ovarian cancer. A comparative immunohistochemical and immunocytochemical study of two commercial monoclonal antibodies (OV632 and OC125). Am J Clin Pathol 1988;90:391-6.
110. Abati A, Fetsch PA. OV632 as a possible marker for malignant mesothelioma: high expectations; low specificity. Diagn Cytopathol 1995;12:81-2 (letter).
111. Geiger B, Ayalon O. Cadherins. Annu Rev Cell Biol 1992;8:307-32.
112. Takeichi M. Cadherin cell adhesion receptors as morphogenetic regulators. Science 1991;251:1451-5.
113. Gumbiner B, Simons K. A functional assay for proteins involved in establishing an epithelial occluding barrier: identification of a uvomorulin-like peptide. J Cell Biol 1986;102:457-68.
114. Redies C, Engelhardt K, Takeichi M. Differential expression of N- and R-cadherin in functional neuronal systems and other structures of the developing chicken brain. J Comp Neurol 1993;333:398-416.
115. Okazaki M, Takeshita S, Kawai S, et al. Molecular cloning and characterization of OB-cadherin, a new member of Cadherin family expressed in osteoblasts. J Biol Chem 1994;269:12092-8.
116. 2+-dependent adhesion molecule, N-cadherin, in myoblast interaction during myogenesis. Exp Cell Res 1990;188:175-84.
117. Peralta Soler A, Knudsen KA. N-cadherin involvement in cardiac myocyte interaction and myofibrillogenesis. Dev Biol 1994;162:9-17.
118. Hatta K, Takagi S, Fujisawa H, et al. Spatial and temporal expression pattern of N-cadherin cell adhesion molecules correlated with morphogenetic processes of chicken embryos. Dev Biol 1987;120:215-27.
119. Peralta Soler A, Knudsen KA, Jaurand M-C, et al. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 1995;26:1363-9.
120. Han AC, Soler AP, Knudsen KA, Salazar H. Exclusive expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed paraffin-embedded archival tissues. Lab Invest 1996;74:156A (abstract).
121. Tiniakos DG, Healicon RM, Hair T. Wadehra V, Horne CHW, Angus B. p53 immunostaining as a marker of malignancy in cytologic preparations of body fluids. Acta Cytol 1995;39:171-6.
122. Kafiri G, Thomas DM, Shepherd NA, Krausz T, Lane DP, Hall PA. p53 expression is common in malignant mesothelioma. Histopathology 1992;21:331-4.
123. Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol 1992;168:377-81.
124. Ross R. Platelet-derived growth factor. Lancet 1989;1:1179-82.
125. Ramael M, Buysse C, Van den Bossche J, Segers K, Van Marck E. Immunoreactivity for the β chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992;167:1-4.
126. Dardick I, Butler EB, Dardick AM. Quantitative ultrastructural study of nuclei from exfoliated benign and malignant mesothelial cells and metastatic adenocarcinoma cells. Acta Cytol 1986;30:379-84.
127. Burns TRI, Johnson EH, Cartwright J Jr, Greenberg SD. Desmosomes of epithelial malignant mesothelioma. Ultrastruct Pathol 1988;12:385-8.
128. Ordóñez NG, Myhre M, Mackay B. Clear cell mesothelioma. Ultrastruct Pathol (in press).
129. Warhol MJ, Corson JM. An ultrastructural comparison of mesotheliomas with adenocarcinomas of the lung and breast. Hum Pathol 1985;16:50-5.
130. Dardick I, Jabi M, McCaughey WTE, Deodhare S, van Nostrand AWP, Srigley JR. Diffuse epithelial mesothelioma: a review of the ultrastructural spectrum. Ultrastruct Pathol 1987;11:503-33.